The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
Launched by UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY · Oct 17, 2024
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with sq-NSCLC;
- • Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
- • ≥ 18 years and ≤ 80 years old;
- • No previous treatment in the lungs or any other organ.
- Exclusion Criteria:
- • History of cancer treatment;
- • History of other malignant tumors;
- • Irregular treatment or poor compliance;
- • Incomplete clinical information or lost to follow-up.
About Union Hospital, Tongji Medical College, Huazhong University Of Science And Technology
Union Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology, is a leading comprehensive medical institution in China. Renowned for its advanced clinical services, cutting-edge research, and commitment to medical education, the hospital integrates patient care with innovative scientific investigation. As a prominent sponsor of clinical trials, Union Hospital plays a vital role in advancing medical knowledge and improving healthcare outcomes through rigorous research and collaboration.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Xueyun Tan, MD
Study Director
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Yang Jin, PHD
Principal Investigator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported